Fig. 7
The synergistic effect of combination treatment with TMQ0153 and FLT3-targeting gilteritinib in the MV4-11 cell line and MOLM-14-luc xenograft study. A MV4-11 cells were treated with increasing concentrations of gilteritinib for up to 72 h, and cell viability was assessed using a trypan blue staining assay. B Cell proliferation following gilteritinib treatment. C Cell death was evaluated using AV/PI staining after combination treatment with TMQ0153 and gilteritinib. D Total cell numbers were measured by trypan blue staining after combination treatment. E The synergistic effect was analyzed using Compusyn software. F Colony formation assays were conducted following single or combination treatments in the MV4-11 cell line, with the number and total area of colonies indicated. G The scheme for the xenograft study using MOLM-14-luciferase (luc) cells. H Bioluminescence images, (I) survival curves, (J) body weight, and (K) total flux measurements in MOLM-14-luc-bearing NRG. TMQ0153 (35 mg/kg; intraperitoneal injection every 3 days) and gilteritinib (3 mg/kg; oral gavage daily) were administered alone or in combination. N = 5 mice/group. Statistical significance is denoted as *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data were analyzed using one-way ANOVA with Dunnett’s (A, K) and Tukey’s (B-D and F) Multiple Comparison tests. Survival curves were compared using the log-rank test (TMQ0153: P = 0.0072, gilteritinib: P = 0.0072, TMQ0153 + gilteritinib: P = 0.0021). A.u.: arbitrary units, CI: combination index, Fa: fraction affected, BLI: Bioluminescence imaging